

SGK3 (CISK) may induce tumor angiogenesis (Hypothesis)

MINZHI HOU¹, YINGRONG LAI², SHANYANG HE¹, WEILING HE³, HONGWEI SHEN¹ and ZUNFU KE²

Departments of ¹Gynecology, ²Pathology and ³Gastrointestinal Surgery,
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China

Received July 24, 2014; Accepted March 27, 2015

DOI: 10.3892/ol.2015.3182

Abstract. Serum- and glucocorticoid-inducible protein kinase 3 (SGK3), also known as cytokine-independent survival kinase (CISK), encoded by chromosome 8q12.2, is a downstream mediator of phosphatidylinositol 3-kinase (PI3K) oncogenic signaling. As a downstream target of PI3K, SGK3 has been reported to mediate pivotal roles in oncogenic progress in various cancers, including breast cancer, ovarian cancer and hepatocellular carcinoma. Functionally parallel to v-akt murine thymoma viral oncogene homolog (AKT)/protein kinase B, SGK3 serves as a hallmark mediating glycogen synthase kinase- β (GSK3- β), B-cell lymphoma (Bcl)-2-associated death promoter, forkead family of transcription factors, Bcl-extra large, Bcl-2, mammalian target of rapamycin, C-X-C chemokine receptor type 4 (CXCR4) and numerous other molecules in cell proliferation, growth, survival, migration and even tumor angiogenesis. Tumor angiogenesis is recognized as an essential step for tumor growth, invasion and metastasis, and it has become an intriguing target for anticancer drug development for tumor investigators worldwide. An abundance of experiments have been performed to investigate the role of the phosphoinositide 3-kinase (PI3K)/AKT pathway in regulating tumor angiogenesis. The mechanism of angiogenesis regulated by the PI3K/AKT pathway is, to a certain extent,

clear. Although a number of SGK3 target molecules, including CXCR4 and GSK3 β , have demonstrated potential roles in promoting angiogenesis, the exact association between angiogenesis and SGK3 remains unclear. Thus, we hypothesize that SGK3, parallel to AKT, may also be important in mediating angiogenesis. Identifying the role of SGK3 in tumor angiogenesis will certainly present a novel perspective on the malignant transformation of tumors, as well as a target for tumor therapy.

Contents

1. Introduction
2. Hypothesis
3. Evidence and discussion
4. Clinical implications

1. Introduction

V-akt murine thymoma viral oncogene homolog [SGK3; also known as cytokine-independent survival kinase (CISK)], as a downstream target of the phosphoinositide 3-kinase (PI3K) cascade and a member of the AGC family of kinases, has certain similar substrates and shares certain target-signaling molecules with v-akt murine thymoma viral oncogene homolog (AKT) in cell proliferation, growth and survival (1-4). SGK3 is a serine/threonine protein kinase, and its key phosphorylation sites are Thr²⁵⁶ and Ser⁴²² (5). The residues of SGK3 (also known as CISK) equivalent to those of AKT are targeted by 3-phosphoinositide-dependent kinase 1 (PDK1) and PDK2 respectively (5). Functionally parallel to AKT, SGK3 is involved in the malignant transformation of tumors by regulating cell proliferation, cell growth, cell survival and cell migration (4,6,7). The oncogenic effect of SGK3 in tumors has been demonstrated by *in vitro* and *in vivo* functional assays (2,3). Xu *et al* (2) reported that the positive correlation between SGK3 expression and tumor prognosis varies with tumor grade and lymph node status. Angiogenesis is a key process in tumor malignant transformation, which involves blood vessel endothelial cell proliferation and migration. The signaling pathways of the cellular processes that SGK3 mediates, particularly in cell survival, have been well studied. However, angiogenesis, another tumor malignant transformation process, is seldom reported in comparison to AKT. Therefore, the present study aims to find evidence that SGK3 may be involved in angiogenesis.

Correspondence to: Professor Zunfu Ke, Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, Guangdong 510080, P.R. China
E-mail: kezunfu@126.com

Professor Hongwei Shen, Department of Gynecology, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road II, Guangzhou, Guangdong 510080, P.R. China
E-mail: shenhw@mail.sysu.edu.cn

Abbreviations: PI3K, phosphoinositide 3-kinase; PDK1, 3-phosphoinositide-dependent kinase 1; AKT, v-akt murine thymoma viral oncogene homolog; SGK3, serum- and glucocorticoid-inducible protein kinase 3; CISK, cytokine-independent survival kinase; Bcl-xL, B-cell lymphoma-extra large; FKHRs, forkhead family of transcription factors; BAD, Bcl-2-associated death promoter; GSK3- β , glycogen synthase kinase- β ; CXCR4, C-X-C chemokine receptor type 4; VEGF, vascular endothelial growth factor

Key words: GSK-3 β , PI3K, VEGF, angiogenesis




Figure 1. Signaling of SGK3 and AKT. Activation of PI3K leads to phosphorylation of PDK1, subsequently leading to phosphorylation and activation of AKT and SGK3. Cell survival and cell growth/proliferation: By regulating the downstream function in cell survival (Bcl-xL, BAD, FKHRs, GSK3- β) and cell growth/proliferation (GSK3- β , TSC2, PRAS40). SGK3 also induces cell survival by downregulating CXCR4 through the interaction with ubiquitin ligase AIP4. SGK3 mediates ER-positive cancer cells survival by phosphorylating its co-activator, FLI-1. Angiogenesis: PI3K signaling pathways involve in the Foxc2-mediated angiogenesis process. Inhibition of GSK3- β by PI3K/AKT up-regulates the expression of HIF-1 α , which induces VEGF transcriptional activation to promote angiogenesis. ^{*}PI3K/AKT is mediated by Id1 to enhance EPC angiogenesis in ovarian cancer. ^aBy regulating PI3K/PTEN/AKT/GSK3- β pathway, HIV-1 Tat in KSHV vIL-6-induced angiogenesis. SDF-1/CXCR4 receptor ligand system up-regulates VEGF expression to promote angiogenesis. Hypothesis: The red arrow pathways are our hypothesis: SGK3 may involve in tumor angiogenesis by regulating CXCR4 or/and GSK3- β . PI3K, phosphoinositide 3-kinase; PDK1, 3-phosphoinositide-dependent kinase 1; AKT, v-akt murine thymoma viral oncogene homolog; SGK3, serum- and glucocorticoid-inducible protein kinase 3; Bcl-xL, B-cell lymphoma-extra large; FKHRs, forkhead family of transcription factors; BAD, Bcl-2-associated death promoter; FLI-1, flightless-1; GSK3- β , glycogen synthase kinase- β ; TSC2, tuberous sclerosis factor 2; PTEN, phosphatase and tensin homolog; PRAS40, proline-rich AKT substrate of 40 kDa; SDF-1, stromal cell-derived factor 1; CXCR4, C-X-C chemokine receptor type 4; HIF1 α , hypoxia-inducible factor-1 α ; VEGF, vascular endothelial growth factor; Id1, inhibitor of DNA binding/differentiation 1; EPC, endothelial progenitor cell; KSHV vIL-6, Kaposi's sarcoma-associated herpesvirus viral interleukin-6; HIV-1, human immunodeficiency virus type 1; Tat, transactivator of transcription; ER, estrogen receptor; AIP4, atrophin-1-interacting protein 4; FOXC2, forkhead box protein C2; Sp1, specificity protein 1.

2. Hypothesis

An abundance of experiments have been performed to investigate the function of the PI3K/AKT pathway in regulating tumor angiogenesis, and so the mechanism of angiogenesis regulated by the PI3K/AKT pathway is, to a certain extent, clear. However, the association between angiogenesis and SGK3 remains unclear. As they are downstream mediators of the PI3K/PDK1 signaling pathway, AKT and SGK3 have certain similar substrates and share certain targeting molecules. Thus, we hypothesize that a strong signaling connection may exist between angiogenesis and SGK3, contributing to tumor malignant transformation.

3. Evidence and discussion

The deteriorative progress of tumor growth includes several alterations that collectively dictate malignant transformation,

including insensitivity to growth-inhibitory signals, evasion of cell apoptosis, limitless cell proliferation, sustained angiogenesis, and tissue invasion and metastasis (8). SGK3, a downstream effector of PI3K, induces several pro-malignant pathways through the PI3K/PDK1/SGK3 route. Functionally parallel with AKT (Fig. 1) (3,4), SGK3 participates in cell growth, cell survival and cell migration (1,2,9,10). In contrast to the AKT pleckstrin homology domain, SGK3 contains a phox homology domain, through which SGK3 binds to phosphatidylinositol 3-phosphate-rich endosomal and vesicular compartments to remain active. Overexpression of SGK3 increases cell cycle progression through G₁ by inactivating glycogen synthase kinase- β (GSK3- β) and stabilizing CCND1, as previously observed in hepatocellular carcinoma (3,7,9). Similar to AKT, SGK3 is involved in cell growth signaling by the increase of phosphorylated tuberous sclerosis factor 2, ribosomal protein S6, proline-rich AKT substrate of 40 kDa and eIF4E-binding protein 1 in normal

cell physiology and malignant transformation (9,11). Induced by interleukin (IL)-3 (4), SGK3 increases the level of B-cell lymphoma-extra large (Bcl-xL), and inhibits the pro-apoptotic proteins Bcl-2-associated death promoter (BAD) and forkhead family of transcription factors (FKHRs) (3,4,9,10), thus promoting cell survival. Consistent with the fact that SGK3 and AKT are functionally parallel, SGK3 and AKT have synergetic responses to the cell survival pathways through Bcl-xL, BAD and FKHRs. SGK3 mediates estrogen receptor-positive cancer cell survival by phosphorylating its co-activator, flightless-I (2,6). Observations by Slagsvold *et al* (12) support the potential role of SGK3 as a cell survival effector by the downregulation of C-X-C chemokine receptor type 4 (CXCR4) through the interaction with ubiquitin ligase atrophin-1-interacting protein 4. CXCR4 is strongly associated with promoting cell invasion, migration and adhesion during the process of metastasis in breast cancer and liver tumor cells (13,14), showing the potentially significant role of SGK3 in cell migration. Thereby, further studies are required to more specifically characterize the role of SGK3 in these processes.

Tumor angiogenesis is recognized as an essential step for tumor growth, invasion and metastasis, and has become an intriguing target of tumor investigators worldwide for the development of anticancer drugs. A number of studies have shown that vascular endothelial growth factor (VEGF)/VEGF receptor are essential in the tumor angiogenesis process (15,16).

Study has also been focused on the role of the PI3K/AKT pathway in angiogenesis (Fig. 1) (17). Inhibition of GSK3- β by PI3K/AKT upregulates the expression of hypoxia-inducible factor-1 α , inducing VEGF transcriptional activation to promote angiogenesis (17). In early 2013, Su *et al* (18) reported that PI3K/AKT is mediated by inhibitor of DNA binding/differentiation 1 to enhance endothelial progenitor cell angiogenesis in ovarian cancer. In a study by You *et al* (19), extracellular signal-regulated kinases and PI3K signaling pathways showed strong involvement in the forkhead box protein C2-mediated angiogenesis process. Zhou *et al* (20) showed the promotion of human immunodeficiency virus type 1 transactivator of transcription in Kaposi's sarcoma-associated herpesvirus viral IL-6-induced angiogenesis by regulating the PI3K/phosphatase and tensin homolog/AKT/GSK-3 β pathway *in vivo*. A recent study revealed that PI3K/AKT is activated by resistin and increases the interaction with specificity protein 1, resulting in the upregulation of VEGF expression to promote angiogenesis (21).

The stromal cell-derived factor 1/CXCR4 receptor ligand system has also been reported to play a potential role in cancer metastases via the upregulation of VEGF expression to promote angiogenesis (22-24).

Bevacizumab, a monoclonal antibody targeted against VEGF, and a number of other anti-angiogenesis molecules have been used in numerous anti-angiogenesis strategies (25). The use of anti-angiogenesis strategies may present a new epoch in tumor research, however, the exact pathway of the angiogenesis mechanism remains unknown.

Since PI3K/AKT plays an important role in tumor angiogenesis, we hypothesize that SGK3, as a downstream target of PI3K and functionally parallel to AKT, may also be involved in the malignant transformation of tumors by promoting angiogenesis. It has also been reported that CXCR4 and GSK3- β ,

both downstream of SGK3, may also have potential capacity in angiogenesis (3,17). These facts demonstrated the potential role of SGK3 in promoting angiogenesis and is evidence that confirms our hypothesis (Fig. 1).

SGK3 has been studied in depth with regard to tumor malignant transformation, but the exact association between angiogenesis and SGK3 is rarely reported. Possible reasons for this include the fact that SGK3 does not significantly correlate with angiogenesis, or that the amplification and overexpression of SGK3 may be an early stage event in tumor growth (3).

In conclusion, the mechanism of SGK3 in oncogenesis is, to a certain extent, clear. However, its role in malignant transformation, particularly in angiogenesis, remains to be elucidated. Based on the present datum, detailed characterization of any role of SGK3 in the promotion of angiogenesis via CXCR4 and GSK3- β , the association between SGK3 and VEGF, and the exact mechanisms behind this are required.

4. Clinical implications

These data generates an overall impression of SGK3 as an important oncogenic signaling mediator, and stresses the vital nature of further research on the elucidation of the signaling mechanisms associated with SGK3 in tumor angiogenesis. Determining the role of SGK3 in tumor angiogenesis will surely present a novel perspective on tumor malignant transformation, as well as a target for tumor therapy.

Acknowledgements

This study was financially supported by grants from the National Natural Science Foundation of China (nos. 30900650/H1615, 81372501/H1615, 81172232/H1615 and 81172564/H1625), the Guangdong Natural Science Foundation (nos. S2012010008378, S2013010015327 and S2012010008270) and the Science and Technology Plan of Guangdong Province (no. 2011B031800025).

References

1. Xu J, Liu D, Gill G and Songyang Z: Regulation of cytokine-independent survival kinase (CISK) by the Phox homology domain and phosphoinositides. *J Cell Biol* 154: 699-705, 2001.
2. Xu J, Wan M, He Q, *et al*: SGK3 is associated with estrogen receptor expression in breast cancer. *Breast Cancer Res Treat* 134: 531-541, 2012.
3. Liu M, Chen L, Chan TH, *et al*: Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. *Hepatology* 55: 1754-1765, 2012.
4. Liu D, Yang X and Songyang Z: Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. *Curr Biol* 10: 1233-1236, 2000.
5. Kobayashi T and Cohen P: Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositol 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. *Biochem J* 339: 319-328, 1999.
6. Xu J, Liao L, Qin J, *et al*: Identification of Flightless-I as a substrate of the cytokine-independent survival kinase CISK. *J Biol Chem* 284: 14377-14385, 2009.
7. Buse P, Tran SH, Luther E, *et al*: Cell cycle and hormonal control of nuclear-cytoplasmic localization of the serum- and glucocorticoid-inducible protein kinase, Sgk, in mammary tumor cells. A novel convergence point of anti-proliferative and proliferative cell signaling pathways. *J Biol Chem* 274: 7253-7263, 1999.

8. Caers J, Van Valckenborgh E, Menu E, *et al*: Unraveling the biology of multiple myeloma disease: Cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. *Bull Cancer* 95: 301-313, 2008.
9. Bruhn MA, Pearson RB, Hannan RD and Sheppard KE: AKT-independent PI3-K signaling in cancer - emerging role for SGK3. *Cancer Manag Res* 5: 281-292, 2013.
10. Ellson CD, Andrews S, Stephens LR and Hawkins PT: The PX domain: a new phosphoinositide-binding module. *J Cell Sci* 115: 1099-1105, 2002.
11. Bruhn MA, Pearson RB, Hannan RD and Sheppard KE: Second AKT: the rise of SGK in cancer signalling. *Growth Factors* 28: 394-408, 2010.
12. Slagsvold T, Marchese A, Brech A and Stenmark H: CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4. *EMBO J* 25: 3738-3749, 2006.
13. Gassmann P, Haier J, Schlüter K, *et al*: CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. *Neoplasia* 11: 651-661, 2009.
14. Müller A, Homey B, Soto H, *et al*: Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410: 50-56, 2001.
15. Cai W and Chen X: Multimodality molecular imaging of tumor angiogenesis. *J Nucl Med* 49 (Suppl 2): 113S-128S, 2008.
16. Ferrara N: VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* 2: 795-803, 2002.
17. Okumura N, Yoshida H, Kitagishi Y, *et al*: PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. *Adv Hematol* 2012: 843085, 2012.
18. Su Y, Gao L, Teng L, *et al*: Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF- κ B/MMP-2 signaling pathways. *J Transl Med* 11: 132, 2013.
19. You W, Gao H, Fan L, *et al*: Foxc2 regulates osteogenesis and angiogenesis of bone marrow mesenchymal stem cells. *BMC Musculoskelet Disord* 14: 199, 2013.
20. Zhou F, Xue M, Qin D, *et al*: HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3 β signaling pathway. *PLoS One* 8: e53145, 2013.
21. Pang L, Zhang Y, Yu Y and Zhang S: Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells. *Int J Mol Sci* 14: 9751-9766, 2013.
22. Koshiba T, Hosotani R, Miyamoto Y, *et al*: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. *Clin Cancer Res* 6: 3530-3535, 2000.
23. Darash-Yahana M, Pikarsky E, Abramovitch R, *et al*: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. *FASEB J* 18: 1240-1242, 2004.
24. Wang J, Wang J, Sun Y, *et al*: Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. *Cell Signal* 17: 1578-1592, 2005.
25. Dandamudi UB, Ghebremichael M, Sosman JA, *et al*: A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. *J Immunother* 36: 490-495, 2013.